Last reviewed · How we verify
Baricitinib Oral Tablet [Olumiant]
Baricitinib Oral Tablet [Olumiant] is a marketed drug developed by Assistance Publique - Hôpitaux de Paris, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Baricitinib Oral Tablet [Olumiant] |
|---|---|
| Also known as | Baricitinib, Olumiant |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: